Trial · NCT06768177
Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)
NCT06768177, Not applicable, Enrolling by invitation, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE). Trials, record NCT06768177. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06768177
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)
- NCT number
- NCT06768177
- Status
- Enrolling by invitation
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- Conditions
- Erectile Dysfunction Due to General Medical Condition, Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction Associated With Type 2 Diabetes Mellitus, Erectile Dysfunctions
- Interventions
- PRP injection, Alprostadil 20 micrograms
- First posted
- 2025-01-10
- Last updated
- 2025-10-02
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in erectile function | 24 WEEKS | Change in erectile function defined as the % of patients in each group achieving MCID in the IIEF-EF domain from baseline to 24 weeks (i.e. 12 weeks after the end of full treatment): * MCID (Minimal clinically important differences) is based on the severity of ED at baseline as: * Improvement of 5 or points more in IIEF score for patients with moderate ED (8-11) at baseline * Improvement of 2 or more points in IIEF score for patients with severe ED (5-7) at baseline |
| Secondary | EHS | 24 WEEKS | Time frame: change from baseline and at 8 weeks, 16 weeks, and 24 weeks Any value above 0 (0 = The penis does not enlarge) |
| Secondary | The percentage of patients in each group who achieve MCID in the IIEF-EF domain from baseline after treatment with PRP | 24 WEEKS | MCID (Minimal Clinically Important Differences) is defined on the severity of ED at baseline as: * An improvement of 5 or more points in the IIEF score for patients with moderate ED (8-11) at baseline * An improvement of 2 or more points in the IIEF score for patients with severe ED (5-7) at baseline |
| Secondary | The percentage of patients in each group who achieve MCID in the IIEF-EF domain from baseline after treatment with prostaglandin | 24 WEEKS | MCID (Minimal Clinically Important Differences) is defined on the severity of ED at baseline as: * An improvement of 5 or more points in the IIEF score for patients with moderate ED (8-11) at baseline * An improvement of 2 or more points |
| Secondary | The difference in the IIEF score from baseline to the end of treatment between the PRP group and the prostaglandin-treated group. | 24 WEEKS | The difference in the IIEF score from baseline to the end of treatment between the PRP group and the prostaglandin-treated group. |
| Secondary | SEP | 24 WEEKS | Change in SEP: * Response to questions 2 and 3 (SEP-Q2: Were you able to insert your penis into your partner's vagina? / SEP-Q3: Did your erection last long enough to allow you to have successful intercourse?) * Change from baseline (= "YES" response) o At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) |
| Secondary | GAQ | 24 WEEKS | Response to GAQ questions 1 and 2 (GAQ-Q1: Has the treatment you are taking improved your erectile function? / GAQ-Q2: If yes, has the treatment improved your ability to engage in sexual activity?) Change at T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) o Change from baseline (= "YES" response) |
| Secondary | QEQ | 24 WEEKS | At T1 (2 weeks after the end of the first cycle), T2 (2 weeks after the end of the second cycle), and T3 (3 months after the end of the complete treatment) o Improvement of 2 or more in the score |
| Secondary | Change in EDITS between PRP vs. prostaglandins | At T1 (2 weeks after the end of the first cycle) and T2 (2 weeks after the end of the second cycle) | At T1 (2 weeks after the end of the first cycle) and T2 (2 weeks after the end of the second cycle) |
| Secondary | Change in TSS between PRP vs. prostaglandins | 3 months after the end of the complete treatment | Change in TSS between PRP vs. prostaglandins at T3 (3 months after the end of the complete treatment) |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06768177
GET https://conductscience.org/api/trials/v1/NCT06768177/registered